Related Experiment Video
Updated: Dec 18, 2025
05:40
Preparation of Agar Bead Embedded Mycobacterium abscessus to Inoculate Immunocompetent Mice Intratracheally
Published on: April 25, 2025
1.3K
Treatment for Mycobacterium abscessus complex-lung disease
Ya-Wei Weng1, Chun-Kai Huang2, Cheng-Len Sy1
1Division of Infectious Disease, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Summary
Nontuberculous mycobacterial lung infections are increasing. Current treatments for Mycobacterium abscessus complex lung disease are often ineffective, necessitating exploration of new therapeutic agents and strategies.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Pulmonology
Background:
- Nontuberculous mycobacterial infections, particularly Mycobacterium abscessus complex (MABC), are a growing global health concern.
- MABC infections frequently affect the lungs, presenting significant treatment challenges due to drug resistance and variable susceptibility.
- Current treatment regimens are often inadequate for achieving a cure in pulmonary MABC disease.
Purpose of the Study:
- To review the medical treatment of Mycobacterium abscessus complex lung disease.
- To evaluate the efficacy of novel therapeutic agents for MABC lung infections.
- To discuss current challenges and future directions in managing MABC pulmonary disease.
Main Methods:
- Literature review focusing on medical treatment strategies for MABC lung disease.
- Analysis of the efficacy of established and emerging drugs, including macrolides, clofazimine, amikacin, tigecycline, and linezolid.
- Consideration of treatment decisions based on disease severity, comorbidities, and drug resistance patterns.
Main Results:
- Macrolides are central to MABC treatment, but resistance can limit efficacy.
- Standard therapies often yield unsatisfactory outcomes for pulmonary MABC.
- Combination therapy, including surgery for limited disease and multidrug regimens, offers the best chance for cure.
Conclusions:
- Effective treatment of MABC lung disease requires careful consideration of antibiotic susceptibility and disease severity.
- New agents like clofazimine, inhaled amikacin, tigecycline, and linezolid show promise but require further investigation.
- Optimizing treatment for MABC lung disease may involve combining medical therapy with surgical intervention.
Related Concept Videos
01:28Pulmonary Tuberculosis V
461
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
461
01:28Pulmonary Tuberculosis II
1.2K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.2K
01:26Pulmonary Tuberculosis IV
421
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
421
01:31Pulmonary Tuberculosis III
791
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
791
01:29Pulmonary Tuberculosis I
734
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
734
01:28Pneumonia IV: Management
660
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
660